Menu

TREAT AHEAD WITH DOVATO

DOVATO SUPPORTS YOUR TREATMENT DECISIONS NOW…

Rapid, potent and durable viral suppression, with fewer medicines than 3DRs[1–3]

Read more

A proven high barrier to resistance in data up to 5 years[4–6]

Read more

A well-established safety profile, with low rates of discontinuation[3,7]

Read more

A simple and convenient single-tablet regimen, also available in a blister pack[3]

Read more

…SO YOU CAN SUPPORT YOUR PATIENT'S FUTURE.

Lower odds of clinically significant weight gain vs. BIC/FTC/TAF (>5% increase from baseline to Week 48)[8]

Fewer clinically significant DDIs with non-ARVs vs. other single-tablet ARV regimens[9]

Read more

A neutral impact on bone biomarkers, and a low renal impact[1,2]

3DR, 3-drug regimen; ARV, antiretroviral; BSA, body surface area; CKD-EPI, chronic kidney disease epidemiology collaboration; DDI, drug-drug interaction; DTG, dolutegravir; eGFR, estimated glomerular filtration rate; HIVTSQ, HIV Treatment Satisfaction Questionnaire;  NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
†Bone and renal biomarkers include GFR from cystatin C chronic kidney disease epidemiology collaboration (CKD-EPI) (mL/min per 1.73m2, creatinine (μmol/L), GFR from creatinine adjusted for BSA (mL/min per 1.73 m2), GFR from creatinine adjusted for BSA (mL/min per 1.73 m2), protein/creatinine (g/mol), retinol binding protein/creatinine (μg/mmol), beta-2 microglubulin/creatinine (mg/mmol), and bone-specific alkaline phosphatase, osteocalcin, procollagen 1 N-terminal propeptide, and type 1 collagen C-telopeptide.[1]
‡Bone and renal biomarkers include eGFR from creatinine, CKD-EPI, mL/min/1.73 m2, eGFR from cystatin C, CKD-EPI, mL/min/1.73 m2, protein/creatinine g/mol, retinol-binding protein/creatinine μ/mmol, beta-2 microglobulin/creatinine mg/mmol, bone-specific alkaline phosphatase, osteocalcin, procollagen 1 N-terminal propeptide, type 1 collagen C-telopeptide.[2]

References:

  1. Cahn P et al. AIDS 2022; 36(1): 39–48.
  2. Osiyemi O et al. Clin Infect Dis 2022; 75(6): 975–986.
  3. DOVATO (dolutegravir/lamivudine) Summary of Product Characteristics (SmPC)
  4. Maggiolo F et al. BMC Infect Dis 2022; 22(1): 782.
  5. Ciccullo A et al. JAIDS 2021; 88(3): 234–237.
  6. Taramasso L et al. AIDS Patient Care STDS 2021; 35(9): 342–353.
  7. Knobel H et al. HIV Res Clin Pract 2023; 24(1): 2239564.
  8. Ryan P, et al. AIDS 2024. OAB3606LB
  9. European AIDS Clinical Society(EACS) Guidelines. Version 12.0. October 2023.

PM-GB-DLL-WCNT-240006. September 2024

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.